Skip to content
Important: This site presents data from the FDA Adverse Event Reporting System (FAERS). A report does not mean the drug caused the event. Full disclaimer.

Compare Drugs in Antibodies

Boost Your Natural Energy & Metabolism

Mitolyn — 6 exotic plants to unlock your body's fat-burning power. 90-day guarantee.

Try Mitolyn Now
Drug Reports Deaths Death Rate Hosp. Life-Threat. Avg Age % Female
ADALIMUMAB 499,856 21,807 4.4% 108,264 8,132 50.9 yrs 67.6%
DUPILUMAB 379,249 1,536 0.4% 17,008 449 44.7 yrs 61.2%
EVOLOCUMAB 149,666 1,723 1.2% 6,890 484 68.1 yrs 58.8%
OCRELIZUMAB 56,186 1,406 2.5% 10,364 629 47.2 yrs 72.5%
ATEZOLIZUMAB 33,703 8,520 25.3% 15,094 1,505 65.3 yrs 39.1%
DARATUMUMAB 27,387 3,941 14.4% 10,205 1,834 66.8 yrs 44.5%
ALIROCUMAB 22,868 426 1.9% 2,227 111 67.2 yrs 60.0%
DURVALUMAB 17,142 5,088 29.7% 5,968 1,387 65.7 yrs 35.1%
PALIVIZUMAB 11,419 1,248 10.9% 6,461 233 0.8 yrs 42.2%
PANITUMUMAB 10,876 1,666 15.3% 3,121 642 63.0 yrs 36.9%

Head-to-Head Comparisons

ADALIMUMAB vs DUPILUMAB ADALIMUMAB vs EVOLOCUMAB ADALIMUMAB vs OCRELIZUMAB ADALIMUMAB vs ATEZOLIZUMAB DUPILUMAB vs EVOLOCUMAB DUPILUMAB vs OCRELIZUMAB DUPILUMAB vs ATEZOLIZUMAB EVOLOCUMAB vs OCRELIZUMAB EVOLOCUMAB vs ATEZOLIZUMAB OCRELIZUMAB vs ATEZOLIZUMAB
← Back to Antibodies Class side effects →